Live Cell Imaging - Industry Growth and Future Analysis

The value of the live cell imaging market stood at USD 2,829.9 million in 2023, and this number is projected to reach USD 5,634.3 million by 2030, advancing at a CAGR of 10.4% during the projection period.

Live cell studies are an effective way of understanding the dynamics of cellular processes and events. For this reason, there has been an increasing adoption of live cell imaging technology in a wide range of fields such as drug discovery, healthcare research, stem cell biology, and cellular environment studies. 

Furthermore, the growing number of chronic diseases, in particular cancer, and the rapid adoption of high-content HHCS screening techniques for drug discovery are contributing to market growth.

Biotechnology and pharmaceutical businesses have accepted numerous progressive methodologies to overcome the challenges of saving time and money during medication safety and toxicity monitoring, one of which is HCS through cell-based assays. The technique is quicker and more precise and provides an advanced success rate than old-style approaches.

In 2023, the North American region led the worldwide industry, with a share of 50%. The supremacy of the continent can be credited to the growing occurrence of severe and chronic illnesses and the rising research and development spending of biotech and pharma businesses. During the projection period, the consumables category is projected to advance with a CAGR of 10.6%. 

The development is because of the increasing R&D in the biotechnology market, which generates a huge need for kits, reagents, and other consumables for lasting and fast live cell imaging and analysis.

Such reagents and consumables help in getting meaningful data, as they reserve cell health long sufficient for experts to extract whatever insights they require. Moreover, advanced reagents aid in generating rich data from a single cell, using fluorescent reagent blends in cell cultures. Thus, since consumables need to be obtained recurrently, the category will endure to advance.

Read More

Metagenomic Sequencing Industry IS Led by North America

The value of the metagenomic sequencing market was USD 1,938 million in 2022, which will grow at a rate of 17.20% during the forecast period, touching, USD 6,899 million by 2030.

To learn more about this report: https://bit.ly/3V9xz43

Drug discovery had the largest share of revenue of over 26%, in 2022, and it will continue like this in the years to come as well. This is due to the increasing research in the pharma and biotech industries for new drug discovery, frequently as part of partnerships amongst the stalwarts of the market and academic institutes.

The clinical diagnostics will grow the fastest by the end of this decade, because of the making of tools and software for genomic research and increasing occurrence of infectious ailments.

The sequencing category had the largest share in the metagenomic sequencing market, and it will continue its dominance in the years to come, told by an expert at P&S Intelligence. 

Sequencing techniques are often used by healthcare organizations and researchers for genetic studies, crucial component of genetic testing. The cost of sequence modeling has decreased by about 28% yearly because of tech advancements, which will power its acceptance.

Data processing & analysis will grow significantly because of the rising intricacies in upholding the read data of billions of sequences.

North America had the largest share, of over 42%, in 2022, and it will power at a significant rate in the years to come. This will be credited to the considerable R&D activities in the pharma and biotech sectors, increased the risk of diseases, presence of trustworthy healthcare businesses, and support for the initiation of new R&D facilities.

Furthermore, Europe is growing considerably in the acceptance of this technology as a result of the incidence of prominent market participants. As well, the partnerships between government organizations and the sequencing solution providers are accountable for the advance of the industry. It is also thriving because of the obtainability of cutting-edge genomic sequencing technology.

Due to the increasing incidence of genetic and infectious disease, the demand for metagenomic sequencing systems will grow even more by the end of this decade.

Read More

Cell-Based Assays Market and its Growth Landscape for the Next Few Years

Cell-based assays are commonly used analytical tools to measure the cell proliferation, viability, cytotoxicity, production and screening of compounds. Owing to the rise in cases of chronic disorders and increasing inclination of the government organizations and private firms funding in the health sector, there has been a consistent high demand of new therapeutic drug discovery. In this regard, the cell-based assays have advantage over the conventional animal based models for drug discovery. Cell-based assays utilizes live cell models to investigate the cellular mechanism when exposed to external stimuli and provide precise information about the intracellular molecular targets required in drug discovery screening.  In contrary to the animal based methods, the resultant toxicity and safety measures in cell based assays are monitored at an early stage of an experiment, hence it reduces the additional cost that can be generated due to high failure rates if monitored at a later stage of an experiment. In combination to high-throughput screening techniques, cell- based assays have gained its interest in the area of research and development for primary as well as secondary screening. However, cell-based assay’s experimental instruments and kits are expensive and require high skilled professionals to conduct the procedures as the cost of experimental procedure is relatively high. This acts as one of the key restraining factors governing the cell-based assays markets.

To Lean More About this report: http://bit.ly/33acESt

The global cell-based assays market is anticipated to grow on account of rise in the incidence of chronic diseases, increasing public and private intervention in the area of research and development, inclination towards cell-based assays over traditional biochemical assays, and a sustained increase in the drug discovery activity. According to the Centers for Disease Control and Prevention, 7 out of ten causes of death were due to chronic ailments, in 2014. Additionally, the cell-based assay techniques have many advantages over conventional methodology. The continuous advancement in technological products under cell-based assay along with their cost effectiveness are the major drivers of the growth of global cell-based assays market.

Geographically, North America has been the largest region in the global cell-based assays market, mainly attributable to the high public and private funding in the research and development field of cell-based assays market. North America is expected to remain the largest market in the global market during the period 2017 – 2023, followed by the Europe. Asia-Pacific is expected to witness the highest growth during the forecast period with, countries such as China, Japan and India expected to be the growing centers of the cell-based assay market in the region.

Some of the major players operating in the global cell-based assays market include Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., BioTek Instruments Inc., Lonza Group, ProQinase GmbH, Charles River Laboratories Inc, Cisbio Bioassays, Miltenyi Biotec, Cell Biolabs, Inc.,  DiscoverX Corporation, BioAgilytix Labs., Enzo Life Sciences, Inc., Aurelia Bioscience Ltd., Selexis SA, and QGel SA.

Read More